ClinicalTrials.gg
RecruitingNCT07857070NBTUpdated Nov 10, 2026

Newborn Brain Assessment - CergenX Wave

An observational study in Neonatal Encephalopathy, Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy) and Neonatal Encephalopathy, Unspecified, sponsored by CergenX Limited. Recruiting at 2 sites in 2 countries. Open to participants aged 36 Weeks and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by CergenX Limited · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
165
Ages
36 Weeks and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Hypoxia-Ischemia, Brain with a site in United States — 27 open to participants now, 34 under way, 1 of them phase 3. Hypoxia-Ischemia, Brain · United States.

Planned enrollment
10th of 31
165 · median 78
Started
2026
with 5 others
Observational
31 of 84
15 open now
Primary completion
2027-10
later than 21 of 33 live
Registered
84th of 84
by date

Among the 84 studies in Hypoxia-Ischemia, Brain with a site in United States, this one is the 10th largest by planned enrollment of the 31 observational ones that give a count, is one of 6 that started in 2026, is one of 31 observational ones, reaches primary completion later than 21 of the 33 other live ones, and was the 84th registered.

Hypoxia-Ischemia, Brain

261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.

Browse Hypoxia-Ischemia, Brain studies →

Open to participants now

27 of the 84 studies in Hypoxia-Ischemia, Brain with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.

This study: 36 Weeks and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Hypoxia-Ischemia, Brain with a site in United States, or all of them as a file.
02

Study summary

In this study we want to assess how a newly developed software device called CergenX Wave compares to the modified Sarnat examination, performed by the neonatology team . The Wave software algorithm (which is a set of rules used by the computer) analyses EEG activity, using four electrodes placed on the neonate's scalp.

A portable EEG machine records the EEG activity and a tablet will send this information to the cloud where the device analyses the data, as shown in the figure below. The EEG activity the Wave device evaluates will not be available to either the research or clinical team during the investigation but once the recording is completed the device will display a code on screen for the research team to confirm completion.

The results will not be visible to either the researchers or the clinical team therefore will not in any way influence the care of the neonate. This is a regulated observational investigation to compare how the software performs against the current standard of care, a standardised neurological examination.

03

Conditions studied

  • Neonatal Encephalopathy
  • Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy)
  • Neonatal Encephalopathy, Unspecified
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
36 Weeks and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Infants at high-risk of Neonatal Encephalopathy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infants born at ≥36+0 weeks gestational age
  2. obtained AND
  3. A pH of ≤7.0 or base deficit ≥16 (on cord or 1st infant blood gas at \< 1 hour of life) OR
  4. a) A pH of 7.01-7.15 or base deficit of 10-15.9 (on cord or 1st infant blood gas at \< 1 hour of life) WITH b) at least one of the following:

    • An APGAR score ≤5 at 10 minutes OR
    • Prolonged resuscitation (infant receiving IPPV at ≥10 minutes of life) OR
    • An acute perinatal event:

      • Abnormal CTG (variable/late foetal HR decelerations)
      • Foetal bradycardia
      • Prolapsed/ruptured/tight nuchal cord
      • Shoulder dystocia
      • Uterine rupture
      • Maternal haemorrhage/placental abruption
      • Maternal trauma (e.g. vehicle accident)
      • Mother received CPR

Exclusion criteria

Exclusion Criteria:

  1. Infants \< 36 weeks gestation
  2. No parental/guardian consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
165 participants (estimated)
Patient registry
No

Groups and cohorts

  • Neonates

    Neonates at risk of Neonatal Encephalopathy

    Device: CergenX Wave

Interventions

  • DeviceCergenX Wave

    The amplifier is used to acquire and transmit the EEG to the CergenX Wave software that is installed in a COTS computer.

    Also known as: eego amplifier

06

What researchers measure

Primary outcomes

  1. Percentage agreement between the CergenX Wave result and stage of NE assigned by modified Sarnat examination (i.e. normal/mild abnormality versus moderate/severe abnormality) between 1-6 hours of life

    Time frame: From the enrolment and up to 6 hours after birth

Secondary outcomes

  1. Change in agreement between the modified Sarnat examination and the software-based assessment from the initial assessment (1-6 hours of life) to 24 hours of life (± 6 hours) among infants with initial disagreement.

    Time frame: From enrolment of the participant and up to 30 hours after birth

  2. Level of agreement between modified Sarnat examination, Wave software, and aEEG/cEEG classification at the same time point in infants with available neurophysiologic monitoring.

    Time frame: From enrolment of the participant and up to 30 hours after birth

  3. Association between CergenX Wave software and clinical variables including discharge diagnosis

    Discharge diagnoses will be based on the clinical teams ultimate determination, and for analysis will be stratified as perinatal asphyxia without encephalopathy, mild neonatal encephalopathy, moderate encephalopathy, severe encephalopathy or alternate diagnosis. Descriptive statistics will be used to explore the frequency of the output of the Wave device with these diagnoses

    Time frame: From enrolment of the participant and up to 30 hours after birth

  4. Assessment of healthcare professional (device users) satisfaction with usability of the device.

    An adapted System Usability Scale (SUS) will be used, referred to as a User Experience Questionnaire that utilises a Likert scale.

    Time frame: From enrolment of the participant and up to 30 hours after birth

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 50 observational studies under Hypoxia-Ischemia, Brain, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 20. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Sep 2026 → Oct 2026, primary completion Sep 2027 → Oct 2027 and completion Sep 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Oct 5, 2026
StartActual
Oct 22, 2026was Sep 2026
Primary completionEst.
Oct 2027was Sep 2027
CompletionEst.
Oct 2027was Sep 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
Show 2 sites
  • University of Texas Southwestern Medical Center · Dallas, United Statesno status→Not yet recruiting
  • Cork University Maternity Hospital · Cork, Irelandno status→Recruiting
Nov 10, 2026
Start date
Sep 2026→Oct 22, 2026 (actual)
Nov 10, 2026
Primary completion
Sep 2027→Oct 2027
Nov 10, 2026
Study completion
Sep 2027→Oct 2027
Nov 10, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Editeda) A pH of 7.01-7.15 or base deficit ≥ 16of 10-15.9 (on cord or 1st infant blood gas at < 1 hour of life) WITH b) at least one of the following:
Nov 10, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
    Show 2 sites
    • University of Texas Southwestern Medical Center · Dallas, United Statesno status→Not yet recruiting
    • Cork University Maternity Hospital · Cork, Irelandno status→Recruiting
    Start date Sep 2026→Oct 22, 2026 (now actual)
    Primary completion Sep 2027→Oct 2027
    Study completion Sep 2027→Oct 2027
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Editeda) A pH of 7.01-7.15 or base deficit ≥ 16of 10-15.9 (on cord or 1st infant blood gas at < 1 hour of life) WITH b) at least one of the following:
    + 1 other change: verification date
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857070
Lead sponsor
CergenX Limited
Collaborators
INFANT centre, University College Cork, Republic of Ireland
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 22, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Brian Walsh, Neonatologist
Contact
brianhenry.walsh@ucc.ie
+353214920525

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion